



































































Hepatocyte transplantation, a step forward? 
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Hepatocyte transplantation is still to consolidate as a viable therapeutic option for 
patients with hereditary metabolic liver diseases. Although we now oversee five 
decades of basic and animal research in the field, the number of successfully treated 
patients remains low. However, the discrepancy between successful cell 
transplantation in animals and the often marginal therapeutic outcomes in patients is 
striking. Animal experiments are optimally designed to achieve the best possible 
outcomes, and the use of animal models that enable a selection growth advantage 
for transplanted cells (i.e., freshly isolated, high quality autologous hepatocytes) can 
serve as an example for a mismatch between basic science experimental scenarios 
with the clinical reality, which relies on heterologous hepatocytes isolated from 
marginal liver donor organs. Attempts to substitute primary isolated heterologous 
hepatocytes with autologous iPS cell derived hepatocytes have remained elusive and 
still await conclusive results for its broader clinical applicability. 
In this issue, Barahman, Guha and colleagues have studied the use of focal radiation 
combined with hepatic cell growth stimulation, as a clinically applicable therapeutic 
modality to increase engraftment and repopulation of a host liver with transplanted 
hepatocytes (1). The apolipoprotein E “knock out receptor deficient mouse model”, 
which they have used, does not provide a selection advantage for transplanted cells 
and has thus rarely been used in earlier studies. The therapeutic outcome was 
analyzed not only histochemically by calculating the number / percentage of 
successfully engrafted cells, but also monitored by increased ApoE levels and 
reduced cholesterol, LDL, VLDL levels in serum. Infusion of hepatocytes via portal 
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vein or into the spleen usually results in less than two percent of engrafted cells and 
would not significantly change lipid serum levels in this mouse model. The authors of 
the study explored a strategy based on regional high dose irradiation of mice liver 
combined with hepatic cell growth stimulation and analyzed the effects on 
engraftment and functionality of hepatocyte transplantation. Previous studies of the 
Guha group and others had already shown a dose dependent inhibitory effect on 
proliferation of liver hepatocytes with maintenance of liver function and only a slow 
clearance of the irradiated cells (2). Radiation therapy (50 Gy) was restricted to 
median and right lobes of the mouse liver. Although this focal radiation of the host 
liver may diminish the therapeutic effects of transplanted cells, in turn, it reduces the 
risk of liver failure in unsuccessful cell transplants. 
With this approach the number of transplanted cells was significantly, but not 
impressively increased, as compared to control animals (transplanted without 
irradiation). Initially engrafted hepatocytes would probably increase their number over 
a long period of time, since the irradiated host hepatocytes slowly die after the 
previous high dose irradiation. To accelerate the process of liver repopulation, Guha 
et al used growth stimulators such as adenovirus encoded hepatocyte growth factor 
(HGF), or GC1, a selective agonist of the T3 thyroid hormone β receptor, which elicits 
a strong hepatic mitogen stimuli but has no impact on cardiac function as thyroid 
hormones have. Four month after hepatocyte transplantation the number of 
engrafted hepatocytes had dramatically increased and serum cholesterol, LDL and 
VLDL levels reduced to almost normal levels. Based on these evidences, the authors 
conclude that focal radiation in combination with a hepatic growth stimuli improves 
the therapeutic outcome of hepatocyte transplantation and successfully correct this 
hereditary liver disease in the absence of a selection advantage for transplanted 
cells. Side effects were acceptable with no long term safety concerns, although these 
issues were not in the focus of the study. 
Preparative radiation in the context of hepatocyte transplantation was already 
explored in a pioneer work by Soltys et al., in a small number of non-human primates, 
as a basis for the first-in-man trial, and published in this journal (3). Three patients 
with hereditary liver diseases were transplanted after prior focal irradiation of the 
liver. The results evidenced the clear positive effects of previous liver irradiation, 




































































The study of Guha group convincingly shows the potential of radiation therapy 
combined with hepatocyte growth stimuli to achieve an improved engraftment of 
transplanted hepatocytes, even if there is not a selective advantage for them, and an 
efficient therapeutic correction of an inborn error of the liver. The work provides 
detailed analysis on a cellular and molecular level and gives support for further 
clinical development. Whether the administration of HGF or the agonist GC1 is safe 
and efficient in humans, remains to be determined. Furthermore, few data currently 
exist on long term safety of radiation preconditioning of the liver, especially in 
children. Although no long term consequences have been reported in one 
retrospective study (4), careful monitoring of patients treated with radiation therapy 
and HT is mandatory. 
Partial hepatectomy has been used as a clinical procedure to increase the number of 
successfully engrafted hepatocytes, and has been applied in two patients with 
Crigler-Najjar syndrome, but it did not result in complete correction of the disease (5). 
Other alternative therapeutic approaches to correct hereditary metabolic liver 
diseases are being currently explored. Adeno-associated virus (AAV) used in clinical 
gene therapy protocols (i.e., hemophilia B) with promising results (6), are being 
explored in liver diseases as well (7). Whether this type of gene therapy can be 
successfully applied to newborns and small children remains to be verified, since 
episomal AAV vectors may be lost in a growing liver. More recent studies point at the 
potential of CRISPR/Cas9 based HDR and base editing methods for in vivo 
correction of genetic diseases of the liver (8).  
Currently, we cannot anticipate, which of these advanced therapies will be the one of 
choice to correct hereditary metabolic liver disease in a near future, but Chandan 
Guha and co-workers (1) have clearly shown that hepatocyte transplantation together 
with focal radiation and growth stimuli may be one promising candidate. 
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